

ADVERSE IMPACTS OF SEVERE ASCVD *Is PCSK9 Inhibition the Key to Improve Patient Outcomes?*

Bibliography

- Abifadel M et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet.* 2003;34:154-156.
- Baigent C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. *Lancet.* 2005;366:1267-1278.
- Ballantyne CM et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. *Am J Cardiol.* 2004;93:1487-1494.
- Barth JA et al. Family history of early cardiovascular disease in children with moderate or severe hypercholesterolemia: relationship to lipoprotein (a) and low-density lipoprotein cholesterol levels. *J Lab Clin Med.* 1999;133:237-244.
- Blom DJ et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. *N Engl J Med.* 2014;370:1809-1819.
- Boekhold SM et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. *JAMA.* 2012;307:1302-1309.
- Budha NR et al. Modeling and simulation to support phase 2 dose selection for RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9. *AAPSJ.* 2015;17:881-890.
- Cannon CP et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. *J Am Coll Cardiol.* 2006;48:438-445.
- Cannon CP et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med.* 2015;372:2387-2397.
- Cardiovascularnews. <https://cardiovascularnews.com/aha-2016-the-medicines-company-and-alnylam-pharmaceuticals-present-positive-results-from-orion-1-phase-2-study-of-their-pcsk9-inhibitor-inclisiran>.
- Cohen J et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. *Nat Genet.* 2005;37:161-165.
- Cohen JC et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med.* 2006;354:1264-1272.
- Fitzgerald K et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomized, single-blind, placebo-controlled phase 1 trial. *Lancet.* 2014;383:60-68.
- Giugliano RP, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolemia (LAPLACETIMI 57): A randomised, placebo-controlled, doseranging, phase 2 study. *Lancet.* 2012;380:2007-2017.
- Sullivan D et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients. The GAUSS randomized trial. *JAMA.* 2012;308:2497-2506.
- Gupta N et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. *PLoS One.* 2010;5:e10682.

Grundy SM et al. Third report of the National Cholesterol Education Program expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106:3143-3421.

Kastelein JJ et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: Design and rationale of the ODYSSEY FH studies. *Cardiovasc Drugs Ther*. 2014;28:281-289.

Kastelein JJ et al. Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type (PCSK) a randomized placebo controlled Phase 2 study. *Eur Heart J*. 2016;37:1360-1369.

Kereiakes DJ et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. *Am Heart J*. 2015;169:906-915.

Koren MJ et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study. *Lancet*. 2012;380:1995-2006.

Lindholm M et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. *Mol Ther*. 2012;20:376-381.

Lloyd-Jones DM et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. *J Am Coll Cardiol*. 2016;68:92-125.

Mozaffarian D et al. Heart Disease and Stroke Statistics-2016 Update: A report from the American Heart Association. *Circulation*. 2016;133:e38-e360.

Nicholls SJ et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients, The GLAGOV Randomized Clinical Trial. *JAMA*. 2016;316:2373-2384.

Nissen SE et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with musclerelated statin intolerance, the GAUSS-3 randomized clinical trial. *JAMA*. 2016;315:1580-1590.

Raal FJ et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. *Circulation*. 2012;126:2408-2417.

Reiner Z. Resistance and intolerance to statins. *Nutr Metab Cardiovasc Dis*. 2014;24:1057-1066.

Bitzur R et al. Intolerance to statins: mechanisms and management. *Diabetes Care*. 2013;36:S325-S330.

Ridker PM et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195-2207.

Robinson JG et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med*. 2015;372:1489-1499.

Rosenson RS et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. *J Am Coll Cardiol*. 2015;65:270-277.

Sabatine MS et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017 Mar 17. [Epub ahead of print].

Sabatine MS et al. Rationale and design of the further cardiovascular outcomes research with pcsk9 inhibition in subjects with elevated risk trial. *Am Heart J*. 2016;173:94-101.

Schroeder KM et al. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. *J Lipid Res.* 2015;56:2124- 2132.

Schwartz GG et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. *Am Heart J.* 2014;168:682-689.

Sniderman AD et al. The severe hypercholesterolemia phenotype, clinical diagnosis, management, and emerging therapies. *J Am Coll Cardiol.* 2014;63:1935-1947.

Stone NJ et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. *J Am Coll Cardiol.* 2014;63:2889-2934.

Surdo PL et al. Mechanistic implications for LDL receptor degradation from PCSK9/LDLR structure at neutral pH. *EMBO Rep.* 2011;12:1300-1305.

Toth PP. Antisense therapy and emerging applications for the management of dyslipidemia. *J Clin Lipidol.* 2011;5:441-449.

Waters DD et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. *Circulation.* 2009;120:28-34.

Weinreich M, Frishman WH. Antihyperlipidemic therapies targeting PCSK9. *Cardiol Rev.* 2014;22:140-146.